UNSPSC 51282703: Vancomycin hydrochloride

This classification denotes an antibiotic with the molecular formula C66H75Cl2N9O24.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71WO621TJD, chemically known as vancomycin, monohydrochloride but generally known as vancomycin hydrochloride, which bears US NIH Compound Identifier 14970. European Medicines Agency schedules Vancomycin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05077MIG. Most nations schedule vancomycin hydrochloride under HS 29419000 and SITC 54139.

UNSPSC 51282703 Vancomycin hydrochloride is a Commodity code that nominally describes a specific antibiotic product, but recent state and local procurement activity tagged under this code does not consistently reflect vancomycin procurement. Instead, opportunities posted under the code span a much broader range of pharmaceutical and medical supply categories, including naloxone and drug deactivation systems, multi-source generic pharmaceuticals and over-the-counter products, direct-to-manufacturer prescription programs, and emergency medical supplies for fire rescue operations. The mix of issuing bodies includes county health departments, state health and human services commissions, municipal purchasing departments, and cooperative purchasing alliances serving multiple state and local jurisdictions. The scope of work reflects fragmented demand across community health initiatives, pharmacy benefit programs, emergency medical response, and institutional healthcare supply chains, with vendors typically required to meet cGMP and FDA compliance, maintain specific insurance coverage, and support electronic data interchange and inventory management systems.

Recent activity spans Florida, Texas, Minnesota (serving multiple states including Oregon), and the Tampa area. Representative opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) to explore direct-to-manufacturer prescription programs; the City of Tampa's IFB 26P00145 (posted March 25, 2026) for 169 line items of medical and first aid supplies totaling an estimated $700,000 with a March 13, 2026 deadline and SLBE set-aside with a 5 percent bid discount; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026) for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and two-year contract terms effective July 1, 2026.